BibTex RIS Cite

Statin ve fibrat kombinasyonuna bağlı rabdomiyoliz gelişimi ile ilişkili akut böbrek yetmezliği: iki olgu sunumu

Year 2009, Volume: 31 Issue: 2, 164 - 168, 17.03.2009

Abstract

Özet

Son yıllarda, kardiyovasküler hastalıklarda mortalite ve morbiditeyi azalttıkları için statin ve fibrat türevi ilaçların kullanımı artmıştır. Diğer yandan bu ilaçların kullanımına bağlı olarak giderek artan oranlarda rabdomiyoliz ve akut böbrek yetmezliği (ABY) olguları görülmektedir. Rabdomyoliz; travmatik veya nontravmatik nedenlere bağlı olarak çizgili kas hücrelerinin hasara uğraması ile oluşan klinik tablodur. Klinik seyir asemptomatik tablodan, hayatı tehdit eden hipovolemik şok, kardiyak aritmiler ve akut böbrek yetmezliğine kadar değişkenlik gösterebilir. Bu yazıda statin ve fibratın birlikte kullanımına bağlı oluşan rabdomiyolize ikincil gelişen iki ABY olgusu sunuldu.

Anahtar sözcükler: Rabdomiyoliz, akut böbrek yetmezliği, statin, fibrat

 

Abstract

In recent years, the use of statin drugs and fibrat derivative has increased for to reduce mortality and morbidity at the cardiovascular diseases. On the other hand, acute renal failure (ARF) and rhabdomyolysis can be seen growing at rates depending on the use of these drugs. Rhabdomyolysis is the clinical picture depending traumatic or nontraumatic causes of damage of striated muscle cell. Clinical course may show variability from asymptomatic table to the hypovolemic life-threatening shock, cardiac arhythmias and acute renal failure. In this article, two ARF cases are presented linked to the secondary development rhabdomyolysis due to the combined use of statin and fibrat.

Keywords: Rhabdomyolysis, acute renal failure, statin, fibrat

References

  • Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore) 2005; 84: 377-85.
  • Haas CE , Magram Y , Mishra A, Rhabdomyolysis and acute renal failure following an ethanol and diphenhidramine overdose. Ann Pharmacother 2003; 37: 538-42.
  • Rodrigez ML, Mora C, Navaro JF, Cerivastatin-induced rhabdomyolisis. Ann Intem Med 2000; 132: 598.
  • Aydin Unal, Edip Torun, Murat Hayri Sipahioglu, Bulent Tokgoz, Mehmet Gungor Kaya, Oktay Oymak, Cengiz Utas. Fenofibrate-induced acute renal failure due to massive rhabdomyolysis after coadministration of statin in two patients. Inter Med 2008; 47: 1017- 19.
  • Schech S, Graham D, Staffa J, Andrade SE, La Grenade L, Burgess M, Blough D, Stergachis A, Chan KA, Platt R, Shatin D. Risk factors for statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf 2007;16: 352-8.
  • Ireland JH, Eggert CH, Arendt CJ, Williams AW. Rhabdomyolysis with cardiac involvement and acute renal failure in a patient taking rosuvastatin and fenofibrate. Ann Intern Med 2005; 142: 949-50.
  • Kursat S, Alici T, Colak HB. A case of rhabdomyolysis induced acute renal failure secondary to statin-fibrate-derivative combination and occult hypothyroidism. Clin Nephrol 2005; 64: 391-3.
  • Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292: 2585-90.
  • Antos KA, Williams CD, Baker SK, Philiph PS. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 2006; 119: 400-9.
  • Polderman KH. Acute renal failure and rhabdomyolysis. Int J Artif Organs 2004; 27: 1030- 3.
  • Shepherd J, Vidt DG, Miller E, Harris S, Blasetto J. Safety of rosuvastatin: update on 16.876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology 2007; 107: 433-43.
  • ACC/AHA/NHLBI “Clinical Advisory on the Use and Safety of Statins” Circulation 2002; 106: 1024.
  • Vanholder M, Sever MS, Erek E, Lameire N, Acute renal failure related to crush syndrome: Towards an era of seismo nephrology? Nephrol Dial Transplant 2000; 15: 517-21.
  • Flint OP, Masters BA, Gregg RE, Durham SK, HMG CoA reductase inhibitor-induced myotoxicitiy; pravastatin and lovastatin inhibit the geranylgeranylation of low- molecularweight proteins in neonatal rat muscle cell culture. Toxicol Appl Pharmacol 1997; 145: 99-110.
  • Gadbut AP, Caruso AP, Galper JB. Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin. J Mol Cell Cardiol 1995; 27: 2397-402.
  • Laaksonen R, Jokelainen K, Laakso J, Sahi T, Harkonen M, Tikkanen MJ, Himberg JJ The effect of simvastatin treatment on natural antioxidants in low density lipoproteins and high- energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 1996; 77: 851-4.
  • Rosenson RS: Current overview of statin induced myopathy. Am J Med 2004; 116: 408-16.

Statin ve fibrat kombinasyonuna bağlı rabdomiyoliz gelişimi ile ilişkili akut böbrek yetmezliği: iki olgu sunumu

Year 2009, Volume: 31 Issue: 2, 164 - 168, 17.03.2009

Abstract

Son yıllarda, kardiyovasküler hastalıklarda mortalite ve morbiditeyi azalttıkları için statin ve fibrat türevi ilaçların kullanımı artmıştır. Diğer yandan bu ilaçların kullanımına bağlı olarak giderek artan oranlarda rabdomiyoliz ve akut böbrek yetmezliği (ABY) olguları görülmektedir. Rabdomyoliz; travmatik veya nontravmatik nedenlere bağlı olarak çizgili kas hücrelerinin hasara uğraması ile oluşan klinik tablodur. Klinik seyir asemptomatik tablodan, hayatı tehdit eden hipovolemik şok, kardiyak aritmiler ve akut böbrek yetmezliğine kadar değişkenlik gösterebilir. Bu yazıda statin ve fibratın birlikte kullanımına bağlı oluşan rabdomiyolize ikincil gelişen iki ABY olgusu sunuldu

References

  • Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore) 2005; 84: 377-85.
  • Haas CE , Magram Y , Mishra A, Rhabdomyolysis and acute renal failure following an ethanol and diphenhidramine overdose. Ann Pharmacother 2003; 37: 538-42.
  • Rodrigez ML, Mora C, Navaro JF, Cerivastatin-induced rhabdomyolisis. Ann Intem Med 2000; 132: 598.
  • Aydin Unal, Edip Torun, Murat Hayri Sipahioglu, Bulent Tokgoz, Mehmet Gungor Kaya, Oktay Oymak, Cengiz Utas. Fenofibrate-induced acute renal failure due to massive rhabdomyolysis after coadministration of statin in two patients. Inter Med 2008; 47: 1017- 19.
  • Schech S, Graham D, Staffa J, Andrade SE, La Grenade L, Burgess M, Blough D, Stergachis A, Chan KA, Platt R, Shatin D. Risk factors for statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf 2007;16: 352-8.
  • Ireland JH, Eggert CH, Arendt CJ, Williams AW. Rhabdomyolysis with cardiac involvement and acute renal failure in a patient taking rosuvastatin and fenofibrate. Ann Intern Med 2005; 142: 949-50.
  • Kursat S, Alici T, Colak HB. A case of rhabdomyolysis induced acute renal failure secondary to statin-fibrate-derivative combination and occult hypothyroidism. Clin Nephrol 2005; 64: 391-3.
  • Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292: 2585-90.
  • Antos KA, Williams CD, Baker SK, Philiph PS. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 2006; 119: 400-9.
  • Polderman KH. Acute renal failure and rhabdomyolysis. Int J Artif Organs 2004; 27: 1030- 3.
  • Shepherd J, Vidt DG, Miller E, Harris S, Blasetto J. Safety of rosuvastatin: update on 16.876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology 2007; 107: 433-43.
  • ACC/AHA/NHLBI “Clinical Advisory on the Use and Safety of Statins” Circulation 2002; 106: 1024.
  • Vanholder M, Sever MS, Erek E, Lameire N, Acute renal failure related to crush syndrome: Towards an era of seismo nephrology? Nephrol Dial Transplant 2000; 15: 517-21.
  • Flint OP, Masters BA, Gregg RE, Durham SK, HMG CoA reductase inhibitor-induced myotoxicitiy; pravastatin and lovastatin inhibit the geranylgeranylation of low- molecularweight proteins in neonatal rat muscle cell culture. Toxicol Appl Pharmacol 1997; 145: 99-110.
  • Gadbut AP, Caruso AP, Galper JB. Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin. J Mol Cell Cardiol 1995; 27: 2397-402.
  • Laaksonen R, Jokelainen K, Laakso J, Sahi T, Harkonen M, Tikkanen MJ, Himberg JJ The effect of simvastatin treatment on natural antioxidants in low density lipoproteins and high- energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 1996; 77: 851-4.
  • Rosenson RS: Current overview of statin induced myopathy. Am J Med 2004; 116: 408-16.
There are 17 citations in total.

Details

Primary Language English
Journal Section Case Reports
Authors

Gürsel Yıldız

Yasemin Uygun

Esra Marşan

Meryem Tümuçin

Ferhan Candan

Mansur Kayataş

Publication Date March 17, 2009
Published in Issue Year 2009Volume: 31 Issue: 2

Cite

AMA Yıldız G, Uygun Y, Marşan E, Tümuçin M, Candan F, Kayataş M. Statin ve fibrat kombinasyonuna bağlı rabdomiyoliz gelişimi ile ilişkili akut böbrek yetmezliği: iki olgu sunumu. CMJ. June 2009;31(2):164-168.